NEJM shared a post on X:
“RECITE: In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16).”
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, commented under the NEJM post, adding:
“A long-awaited step forward in supportive oncology.
Romiplostim doesn’t just increase platelets – it preserves chemotherapy continuity. The key question now: will this translate into survival benefit?”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al-Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article.
Other articles about NEJM on OncoDaily.
